Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ? 50%: EMPOWER-Lung 1 subgroup analysis.

Ozguroglu, MustafaSezer, AhmetKilickap, SaadettinGumus, MahmutBondarenko, IgorGogishvili, MirandaTurk, Haci M.2024-06-122024-06-1220210732-183X1527-7755https://doi.org/10.1200/JCO.2021.39.15_suppl.9085https://hdl.handle.net/20.500.14551/25942Virtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 04-08, 2021 -- ELECTR NETWORK[Abstract Not Available]en10.1200/JCO.2021.39.15_suppl.9085info:eu-repo/semantics/closedAccess[No Keywords]Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ? 50%: EMPOWER-Lung 1 subgroup analysis.Conference Object3915Q1WOS:000708120605064